ABSTRACT: The human P2Y 2 receptor (hP2Y 2 R) is a G-protein-coupled receptor that shows promise as a therapeutic target for many important conditions, including for antimetastatic cancer and more recently for idiopathic pulmonary fibrosis. As such, there is a need for new hP2Y 2 R antagonists and molecular probes to study this receptor. Herein, we report the development of a new series of non-nucleotide hP2Y 2 R antagonists, based on the known, non-nucleotide hP2Y 2 R antagonist AR-C118925 (1), leading to the discovery of a series of fluorescent ligands containing different linkers and fluorophores. One of these conjugates, 98, displayed micromolar affinity for hP2Y 2 R (pK d = 6.32 ± 0.10, n = 17) in a bioluminescence-energy-transfer (BRET) assay. Confocal microscopy with this ligand revealed displaceable membrane labeling of astrocytoma cells expressing untagged hP2Y 2 R. These properties make 98 one of the first tools for studying hP2Y 2 R distribution and organization.
■ INTRODUCTION
P2Y receptors (P2YRs) are G-protein-coupled receptors (GPCRs) that are activated by extracellular nucleotides. The P2Y family is composed of eight members, encoded by distinct genes, that can be subdivided into two groups on the basis of their primary signaling through specific G proteins 1 and sequence homology. The first subgroup includes the P2Y 1,2,4,6,11 receptors, which primarily signal though G q , whereas the second subgroup, signaling through G i , encompasses the P2Y 12,13,14 receptor subtypes. 2 Notably, the P2Y 2 receptor (P2Y 2 R) is activated by the endogenous agonists uridine-5′-triphosphate (UTP, hP2Y 2 EC 50 = 140 nM) and adenosine-5′-triphosphate (ATP, hP2Y 2 EC 50 = 230 nM). 3 As P2Y 2 R is predominately G qcoupled, receptor activation leads to the stimulation of phospholipase C, IP 3 release, and the elevation of the intracellular Ca 2+ concentration, as well as the initiation of protein kinase C and the activation of the mitogen-activated proteinkinase cascade.
Defining the clinical role for P2Y 2 R antagonism has been hampered by the lack of high-affinity and druglike receptor antagonists. 4 However, it has been reported that ATP released from tumor-cell-activated platelets induces the opening of the endothelial barrier, leading to the migration of tumor cells and hence cancer proliferation. More importantly, P2Y 2 R was identified as the primary mediator of this effect; a strong reduction of tumor cell metastasis was observed in P2Y 2 R-deficient mice, revealing a therapeutic potential of P2Y 2 R antagonists as antimetastatic agents. 5, 6 Recently, it has been reported that both inflammation and fibrosis were reduced in P2Y 2 R-deficient mice compared with those in wild-type animals. In addition, mechanistic studies have demonstrated that the recruitment of neutrophils into the lungs, the proliferation and migration of lung fibroblasts, and IL-6 production are all key P2Y 2 R-mediated processes. These studies clearly demonstrate the involvement of P2Y 2 R subtypes in the pathogenesis of fibrotic lung diseases in humans and mice and support the development of selective P2Y 2 R antagonists for the treatment of idiopathic pulmonary fibrosis (IPF). 7 To date, the only reported high-affinity P2Y 2 R antagonists were those developed by scientists from AstraZeneca resulting in the non-nucleotide P2Y 2 R antagonist AR-C118925 (1). 8, 9 Several in vivo and ex vivo studies using 1 have been reported that further validate the therapeutic benefits of P2Y 2 R antagonists. Importantly, it was shown that 1, which was reported to be inactive at 10 μM against a panel of 37 other receptors, was able to concentration-dependently antagonize ATPγS-induced mucin secretion in an ex vivo model of human bronchial epithelial cells. 10 In addition, Muller et al. recently demonstrated that 1 was a selective, high-affinity, reversible antagonist of P2Y 2 R. 11 We were drawn to the exciting possibility of using 1 as a chemical template to design new P2Y 2 R antagonists 12 and synthesize fluorescently labeled chemical tools to further probe P2Y 2 R function. 13 Using fluorescence as a means to study GPCRs allows scientists access to a large range of pharmacological techniques that can capture dynamic processes in living cells. 14 In particular, fluorescently labeled receptor antagonists have been developed to target GPCRs, allowing the visualization of GPCR function at the cellular level. 15−17 In addition, fluorescent ligands can be used in resonance-energy-transfer (RET) techniques, in particular those that utilize nanoluciferase (NLuc), to quantify ligand−receptor interactions and determine the affinities of unlabeled ligands. 18 This offers advantages for receptors such as P2Y 2 R for which there are currently no commercially available radio ligands. In addition, as the reported antagonists for P2Y 2 R have mid to high affinities, it is proposed that the fluorescent ligands designed from these might also have affinities in this range. This may prove problematic for techniques which directly monitor fluorescent-ligand binding, but NanoBRET has been shown to display low, nonspecific binding at high fluorescent-ligand concentrations. 18, 19 ■ RESULTS AND DISCUSSION Synthesis and Evaluation of the hP2Y 2 R Antagonists. The medicinal-chemistry strategy involved an initial exploration of the structure−activity relationship (SAR) around 1 in order to enable the design of structural analogues with improved predicted physicochemical properties and to guide our design strategy by highlighting suitable linking sites to attach the fluorophore groups ( Figure 1 and Table 1 ).
1 has previously been shown to have a high lipophilicity (cLogP = 4.2) 20 and poor physicochemical properties for oral delivery. 8 We therefore synthesized the thiazole analogue, 3 (cLogP = 3.8), with little loss of affinity for P2Y 2 R. Replacement of the 2,8-dimethyl-5H-dibenzo[a,d] [7] annulene with a 7-chloro-4H-benzo [5, 6] cyclohepta [1,2-d] thiazole tricyclic ring gave 5 (pK b = 6.5, cLogP = 3.4). 21 In addition, a nonparallel SAR with P2Y 2 R affinity was observed in the replacement of the N-1 thiouracil substituent with a methyl group, which gave compound 6, whereas the corresponding analogue, 4, proved inactive. In order to explore this intriguing finding and study this SAR, we synthesized a range of analogues of 6 (Table 2) .
From the SAR study of 6, it was shown that replacing the thiazole 2-methyl substituent with an amino group increased hP2Y 2 R affinity (compare 6 with 7), whereas a sterically 7.11 ± 0.14 (7) 6 5.99 ± 0.03 (7) a The estimated affinity value for each antagonist (pK b ) was calculated using the Gaddum equation from the shift of the UTPγS concentration− response curve brought about by the addition of a single concentration of the antagonist. The data shown are the means ± SEM, and the numbers of separate experiments are given in parentheses. b IA = inactive; i.e., less than a 50% inhibition of the response to 0.1 μM UTPγS in the presence of a 10 μM concentration of the compound. UTPγS EC 50 = 7.9 ± 1.3 nM (n = 25).
c The literature value is pA 2 = 5.7.
8 a The estimated affinity value for each antagonist (pK b ) was calculated using the Gaddum equation from the shift of the UTPγS concentration− response curve brought about by the addition of a single concentration of the antagonist. The data shown are the means ± SEM, and the numbers of separate experiments are given in parentheses. b IA = inactive; i.e., less than a 50% inhibition of the response to 0.1 μM UTPγS in the presence of a 10 μM concentration of the compound (n = 3).
demanding substituent, such as that in 19, resulted in a complete loss of affinity for hP2Y 2 R. We therefore explored the substitution of the amino group and showed that both compounds with sterically demanding amino groups (8, 9 , and 10) and compounds with cyclic tertiary amines (11, 12 , and 13) were inactive. However, the linear, less sterically demanding alkyl amino groups, such as those in 14, 15, 16, and 17, increased hP2Y 2 R affinity, although the bulkier 2-phenoxyethan-1-amino substituent in 18 resulted in the compound being inactive.
Thus far, all of the compounds synthesized were tested as racemic mixtures. To try and determine whether the activity resided in one enantiomer, the resolution of 14 and 16 was achieved through semipreparative chiral HPLC, and the biology of each of the resolved enantiomers was independently assessed (Table 3) .
From these results, it is possible to see that the hP2Y 2 Rantagonist affinities observed for the racemic compounds 14 and 16 reside largely in enantiomers 20 and 23, respectively. Although some antagonist activity is observed for 21, this may be attributed to residual active enantiomer 20, which constitutes 11% of the sample. Unfortunately, the resolved enantiomers proved to be amorphous powders, and so singlecrystal X-ray determination of their absolute chiralities could not be used for structural determination. However, vibrational circular dichroism was used for 22 and 23, from which spectra were acquired for both samples and fitted to the calculated spectra.
22− 24 The results (Supporting Information) showed that there was a good match between the spectrum of 22 and the calculated spectrum for the (S)-enantiomer; therefore, 23 was assigned as the active (R)-enantiomer ( Figure 2) .
In an attempt to increase affinity within the new series of compounds, we the incorporated key structural features of 14 and 5 to generate compound 24. However, 24 did not demonstrate the expected increase in affinity from the combination of features from 14 and 5 and instead showed a level of hP2Y 2 R affinity ( pK d = 7.02 ± 0.05, n = 4) similar to those of 1 and 3, demonstrating that the SARs within the series of compounds were nonadditive. 25 The synthesis of compounds 2−4 is illustrated in Scheme 1. 8 with ethyl 2-(bromomethyl)thiazole-4-carboxylate followed by a treatment with Lawesson's reagent and saponification gave 2,
8 which was reacted with 2-amino tetrazole via benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate activation to afford 3. In a similar manner, alkylation with methyl iodide followed by a conversion to the thiouracil gave 4 in a good overall yield.
Scheme 2 shows the synthetic route to compounds 5 and 6. The first step involved performing a Heck reaction coupling 3-chloroiodobeneze, 25, to allyl alcohol, and this successfully isomerized in situ yielding the desired aldehyde, 26. This compound was reacted with ethyl dichloroacetate in a Darzens condensation 25 to generate an α-chloro epoxide, which was reacted directly with thioacetamide to afford the desired 2-methylthiazole, 27, with moderate yields achieved over two steps. Freshly prepared sodium ethoxide, generated from sodium metal in dried ethanol, was found to be the optimal base for the Darzens condensation. Saponification gave the carboxylic acid, 28, and treatment with oxalyl chloride generated the acyl chloride, which was immediately cyclized to give the tricyclic ketone, 29, as a single regioisomer. Lithiation of the di-tert-butyl etherprotected uracil, 30, 25 was readily achieved with n-butyllithium, and this compound underwent a 1,2-addition to the ketone, 29, to give the tertiary alcohol, 32. Concomitant deprotection and dehydration resulted in uracil, 33, via heating in trifluoroacetic acid. Although the yield for this reaction was poor, other acidic conditions were ineffective. Alkylation at the N1-position of the uracil was achieved in a one-pot process of silylation with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), alkylation with iodomethane, and subsequent desilylation, which give 34. Finally, a reaction with Lawesson's reagent gave 6. From the uracil intermediate, 33, alkylation with ethyl 2-(bromomethyl) thiazole-4-carboxylate 26 gave 35, which was subsequently reacted with Lawesson's reagent to give 36. Hydrolysis was a The compounds were separated using Phenomenex's Lux 5 μm amylose-2 stationary phase. b The estimated affinity value for each antagonist (pK b ) was calculated using the Gaddum equation from the shift of the UTPγS concentration−response curve brought about by the addition of a single concentration of the antagonist. The data shown are the means ± SEM, and the numbers of separate experiments are given in parentheses.
c IA = inactive; i.e., less than a 50% inhibition of the response to 0.1 μM UTPγS in the presence of a 10 μM concentration of the compound (n = 3). 
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Article followed by a reaction of the resulting carboxylic acid with 5-aminotetrazole and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate to give 5.
In a similar sequence to Scheme 2, aldehyde 26 was reacted with ethyl dichloroacetate, and the resulting crude α-chloro epoxide reacted with thiourea to afford the 2-aminothiazole, 37, which was converted to the 2-chlorothiazole, 38 (Scheme 3). The ethyl ester was hydrolyzed to afford the carboxylic acid, 39, which was converted to the acid chloride and cyclized to the tricyclic ketone, 40. Lithiation of the tert-butyl ether-protected uracil, 31, and a reaction with 40 gave the tertiary alcohol, 41. After screening a range of milder acidic conditions, heating to 140°C with microwave irradiation in acetic acid/1,4-dioxane (1:1) for 10 min was found to be optimal for the formation of the desired uracil intermediate, 42, which was subsequently methylated to give 43. The chlorine atom in compound 43 was readily displaced through a nucleophilic aromatic substitution with a range of primary and secondary amines upon heating under basic conditions. These conditions were unsuccessful when aniline was used, and in this instance, heating in the microwave with hydrochloric acid (catalytic) proved successful in giving 46. Microwave-based conditions were employed for the substitution with ammonia in the synthesis of 45. A Suzuki reaction with phenylboronic acid gave 44. Through the use of Lawesson's reagent, it was then possible to convert these uracil derivatives (44−54) to the respective 4-thiouracil derivatives (6−19) . Through a route analogous to the synthesis of compound 7, it was possible to generate the desired tetrazole analogue, 24. Uracil intermediate 42 was alkylated at the N1-position with ethyl 2-(bromomethyl)thiazole-4-carboxylate to give 57. This compound was reacted with 2-methoxyethylamine to afford 58, which was subsequently reacted with Lawesson's reagent to give the 4-thiouracil, 59. Hydrolysis followed by benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate activation and a reaction with 5-aminotetrazole afforded 24. Synthesis of the hP2Y 2 R Fluorescent Ligands. With a view to developing a series of fluorescent conjugates suitable for both a bioluminescence-resonance-energy-transfer (BRET) ligand-binding assay 18,27−29 and imaging via confocal microscopy, we embarked on a strategy to synthesize BODIPY conjugates, specifically with the dyes BODIPY A (628 nm absorption max, 642 nm emission max) or BODIPY B (503 nm absorption max, 509 nm emission max) as this would allow us the opportunity of ligand choice in future imaging work.
Two positions on the P2Y 2 R-antagonist core structure were considered for the attachment of the linker and fluorophore (Figure 3) . In order to simplify the synthetic chemistry and increase the SARs within the series, we examined the replacement of the furan ring of 1 and the thiazole ring of 2 with 1,3,5-trisubstituted phenyl rings. This would allow the attachment of the acyl tetrazole group in addition to providing a second free carboxylic acid group to which the fluorescent conjugates could be attached. Fortunately, the 3,5-dicarboxylic acid on 60 (hP2Y 2 R pK d = 6.53 ± 0.04, n = 7) was well tolerated with no loss of affinity for P2Y 2 R compared with the affinity of compound 2. Therefore, the first series of compounds had the linker fluorophore attached via the phenyl ring of 60.
Having established that alkoxyalkyl amines are tolerated in terms of activity in the 2-position of the thiazole in the 4H-benzo [5, 6] cyclohepta [1,2-d] thiazol-4-yl) tricyclic rings of compounds of the type shown in Figure 2 , this position was chosen as the second point of attachment of the linker fluorophore. Finally, a third generation of fluorescent ligands were explored that contained the optimal second-generation fluorescent ligand with an incorporated acyl tetrazole functional group.
First-Generation hP2Y 2 R Fluorescent Ligands. The general synthetic route for the first-generation P2Y 2 R fluorescent antagonists is shown in Scheme 4.
Alkylation
annulen-5-yl)pyrimidine-2,4(1H,3H)-dione 8 with dimethyl 5-(bromomethyl)isophthalate followed by a treatment with Lawesson's reagent and the selective hydrolysis of one of the methyl esters gave 61. This carboxylic acid (61) was activated using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate and coupled to form the appropriate amides (62 and 63). The second esters of 62 and 63 were then hydrolyzed and converted to amidotetrazoles (64 and 65). Finally, the Boc protecting group was removed, and the resulting amine was coupled to the fluorophore with the appropriate commercially available BODIPY succinimidyl ester to give a small library of four fluorescent conjugates (66−69).
To determine whether any of these conjugates had affinities for P2Y 2 R and consequently if they could be used in 
Article NanoBRET binding assays, a 1321N1 astrocytoma cell line expressing recombinant P2Y 2 R tagged on its N-terminus with NLuc (NLuc-P2Y 2 R) was generated. The NLuc-tagged P2Y 2 receptors exhibited normal calcium signals (UTPγS EC 50 = 91 ± 12 nM, n = 3). These NLuc-P2Y 2 cells were treated with increasing concentrations of 66−69 and then treated with the NLuc substrate, furimazine, before the resulting BRET signal was monitored. All four compounds showed moderate to low affinities for the NLuc-P2Y 2 R (Table 4) , with conjugates 68 and 69 having higher affinities. However, this did illustrate the power of using NanoBRET to monitor ligand binding to low-affinity receptors.
Second-Generation hP2Y 2 R Fluorescent Ligands. The general synthetic route for the second-generation P2Y 2 R fluorescent antagonists, in which the linker fluorophores are attached to the thiazole rings, is illustrated in Scheme 5.
Nucleophilic displacement of the 2-chloro substituent of 43 by either tert-butyl 3-aminopropanoate or tert-butyl 6-aminohexanoate gave the corresponding tert-butyl esters (70 and 71). Treatment with Lawesson's reagent in 1,4-dioxane at 100°C resulted in the formation of the 4-thiouracils (72 and 73). The carboxylic acids were generated from the tert-butyl esters via TFA-mediated hydrolysis and subsequently coupled with tert-butyl (2-aminoethyl)carbamate or tert-butyl 
Article (2-(2-aminoethoxy)ethyl)carbamate to generate the corresponding amides (74−77). The Boc protecting groups were removed using TFA, and the resulting amines were coupled with the appropriate commercially available BODIPY succinimidyl ester (SE), generating a small library of 14 fluorescent conjugates (78−91). These fluorescent conjugates were initially tested using the aforementioned NanoBRET binding assay at fixed concentrations of 10 μM in the presence or absence of 10 μM 1 (see Figure S1 in the Supporting Information). It was found that 80, 85, 86, and 87 generated the largest specific NanoBRET signals; therefore, their affinities were determined from saturation binding assays, demonstrating the excellent signal-to-noise ratios observed from NanoBRET assays even for low-affinity conjugates ( Figure 4 and Table 5 ).
Reassuringly, the affinities determined for the nonfluorescent P2Y 2 R antagonist, 1, with either 86 (pK i = 7.45 ± 0.13, n = 4) or 87 (pK i = 7.32 ± 0.13, n = 4) were consistent with the affinities determined using the P2Y 2 R functional assay (pK b = 7.51 ± 0.09), demonstrating that the P2Y 2 R fluorescent ligands could be used in a NanoBRET assay for determining the affinities of nonfluorescent P2Y 2 R antagonists. The clear demonstration of the saturable specific binding of these low-affinity fluorescent ligands confirmed the utility of the NanoBRET binding format and the ability to exploit the good signal-tonoise ratio of this proximity-based assay. To explore the opportunity to develop higher-affinity fluorescent conjugates, we embarked on a synthetic strategy to incorporate affinityenhancing acyl-tetrazole functional groups into the fluorescent compounds.
Third-Generation P2Y 2 R Fluorescent Ligands. The general synthetic route for the third-generation P2Y 2 R fluorescent antagonists is illustrated in Scheme 6. The displacement of the chlorine atom in compound 57 with tert-butyl 3-aminopropanoate gave the tert-butyl ester, 92. Treatment with TFA afforded the conversion of the tert-butyl ester to the corresponding acid, which was immediately activated and coupled to tert-butyl (2-aminoethyl)carbamate, 93, with HATU. Hydrolysis of the ethyl ester, activation of the carboxylic acid by benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, and coupling with 5-aminotetrazole gave the amidotetrazole, 94. The Boc protecting group was removed, and the resulting amine was attached to the fluorophore with the appropriate BODIPY succinimidyl ester (Scheme 6).
In contrast to the nonfluorophore compounds 14 and 24, whose affinities hardly changed when their uracil N1-substituents were changed, in three of the four compounds (95−98), there were significant increases in their affinities relative to those of the nonamidotetrazole series (compare 98 with 86, 96 with 85, and 97 with 80; Tables 5 and 6) .
Pharmacological Evaluation of Third-Generation P2Y 2 R Fluorescent Ligands. To further evaluate the utility of the fluorescent ligands in studying the pharmacology of P2Y 2 R, one BODIPY A and one BODIPY B linked fluorescent ligand (97 and 98, respectively) were chosen for further studies. Initially, we confirmed that 97 and 98 still retained the ability to functionally antagonize P2Y 2 R ( Figure 5) . In a Ca 2+ -mobilization assay, modest rightwards shifts of the agonist-dose−response curves were observed for both 10 μM 97 (pK b = 5.69 ± 0.05, n = 8) and 10 μM 98 (pK b = 5.87 ± 0.05, n = 7).
Compounds 97 and 98 bought about clear concentrationdependent increases in BRET ratios in NLuc-tagged-hP2Y 2 R assays ( Figure 6 ). These increases were antagonized by 1 (Figure 6c,d) , yielding pKi values of 7.66 ± 0.11 (n = 9) and 7.38 ± 0.04 (n = 6) for the antagonism of 97 and 98 binding, respectively.
To further evaluate the utility of fluorescent conjugate 98 in the NanoBRET ligand-binding assay, the affinities of a selection of P2Y 2 R antagonists (1, 3, 6, 22, 23, 60 , and 86) and the previously reported stabilized-triphosphate P2Y 2 R antagonist, 99,
8 over a range of P2Y 2 R affinities, were determined in competition binding experiments.
All eight compounds induced concentration-dependent decreases in the specific binding of 98, which enabled their affinities to be determined. There was a good correlation between the values obtained in the NanoBRET assay and those determined in the Ca 2+ -mobilization assay (Table 7) . In addition to those of the antagonists, the NanoBRET assay was also used to estimate the affinity of UTPγS. As there have been no reports of radio ligands for P2Y 2 R, this measurement has not previously been possible. 
Article ■ CONCLUSION We have described the synthesis and evaluation of new examples of acidic hP2Y 2 R antagonists based on the known hP2Y 2 R antagonist, 1. In addition, we have shown the discovery of a new series of neutral hP2Y 2 R antagonists and demonstrated SAR leading to the identification of potent hP2Y 2 R antagonists (such as 20 and 23). In addition, we have shown a stereochemical preference for biological activity within this series, as typified by the resolved examples of 20 versus 21 and 22 versus 23. Vibrational circular dichroism has suggested that in the case of 16, all of the hP2Y 2 R biological activity resides in the (R)-enantiomer (23), although single-crystal X-ray work will be required to confirm this initial stereochemical assignment. The SAR studies led to the identification of suitable linking sites for the attachment of the fluorescent ligands, thus generating three distinct series of fluorescently labeled hP2Y 2 R antagonists. From this extensive synthetic work, two examples (97 and 98) were identified as demonstrating both functional antagonist activities (in Ca 2+ -mobilization assays) and sufficient affinities for hP2Y 2 R through a new bioluminescenceresonance-energy-transfer (BRET) assay. In addition, confocal microscopy revealed clear, displaceable membrane labeling of astrocytoma cells expressing hP2Y 2 R. These excellent imaging properties make 97 and 98 ideal tools for studying hP2Y 2 R distribution and organization. Finally, the discovery of the new hP2Y 2 R-antagonist fluorescent ligands (97 and 98) became realized as a result of an extensive program of synthetic chemistry, in which it proved essential to explore the parallel changes of linker-attachment points, fluorophores, and linking groups. 30 From this study, only a few fluorescent conjugates were shown to possess sufficient affinities to enable the establishment of a new NanoBRET-based fluorescent assay for the identification of new hP2Y 2 R fragments and ligands.
■ EXPERIMENTAL SECTION
Chemistry General Methods. Chemicals and solvents were provided by Fisher Scientific UK, Acros Organics, Sigma-Aldrich, Merck Millipore, or Fluorochem. BODIPYFL-X-NHS (D6102) and BODIPY630/650-X-NHS (D10000) were purchased from Molecular Probes (Invitrogen). All reactions were monitored by TLC using Merck Silica Gel 60 Å F254 TLC plates or by LC-MS. Unless otherwise stated, all compounds were dried under high vacuum either at rt or in an oven at 40°C. LC-MS data was collected on a Shimadzu UFLCXR HPLC system coupled to an Applied Biosystems API 2000 electrospray-ionization (ESI) LC-MS/MS. The column used was a Phenomenex Gemini-NX (3 μm, 110 Å, C18, 50 × 2 mm), and it was operated at 40°C. The flow rate was 0.5 mL/min, and UV detection was at 220 and 254 nm. LC-MS method 1 was 5% B for 1 min, 5−98% B over 2 min, 98% B for 2 min, 98−5% B over 0.5 min, and then 5% B for 1 min. LC-MS method 2 was 10% B for 1.5 min, 10−98% B over 
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Article 8 min, 98% B for 2 min, 98−10% B over 0.5 min, and then 10% B for 1 min. Solvent A was 0.1% formic acid in water, and solvent B was acetonitrile. Unless otherwise stated, the compounds reported had purities >95% at the wavelength and method quoted. HRMS data was collected on a Bruker microTOF II mass spectrometer using electrospray ionization (ESI-TOF). Adducts within errors of ±10 ppm were reported. Preparative RP-HPLC was performed on a Waters 2767 sample manager coupled to Waters 2525 binary-gradient module and a Waters 2457 dual-wavelength absorbance detector. The column used was a Phenomenex Gemini-NX (5 μm, 110 Å, C18, 150 × 21 mm) at ambient temperature. The flow rate was 40 mL/min, and UV detection was at 254 nm. Preparative-RP-HPLC method 3 was 10% B for 1 min, 10−35% B over 4 min, 35−40% B over 20 min, 40−90% B over 2 min, 90−10% B over 2 min, and then 10% B for 1 min. Table 6 . (17) a See Scheme 6. b A and B correspond to the R groups in Scheme 6. c The pK d values were derived from saturation binding curves. The data shown are the means ± SEM, and the numbers of separate experiments are given in parentheses. 
Article Preparative-RP-HPLC method 4 was 10% B for 1 min, 10−45% B over 4 min, 45−50% B over 20 min, 50−90% B over 2 min, 90−10% B over 2 min, and then 10% B for 1 min. Solvent A was 0.1% trifluoroacetic acid in water, and solvent B was 0.1% trifluoroacetic acid in acetonitrile. Chiral-HPLC was performed on a Dionex ICS-3000 SP single pump coupled to a Rheodyne 9725i PEEKinjector with a Dionex UltiMate 3000 Variable Wavelength Detector. The columns used for the analytical and semipreparative runs were 250 × 4.6 mm and 250 × 10 mm Phenomenex Luxes (5 μm, Amylose-2), respectively. These operated at ambient temperature, and unless otherwise stated, the mobile phase was 25% ethanol/hexane with a flow rate of 1 mL/min for the analytical runs and 5 mL/min for the semipreparative runs. UV detection was at 254 nm. NMR spectroscopy was performed with a Bruker AV(III) HD 400 NMR spectrometer equipped with a 5 mm BBFO+ probe, which recorded the 1 H and 13 C NMR at 400.25 and 100.66 MHz, respectively, or with a Bruker AV(III) 500 NMR spectrometer equipped with a 5 mm dual 1 H/ 13 C helium-cooled cryoprobe, which recorded the (6) a The data shown are the means ± SEM, and the numbers of separate experiments are given in parentheses. b The estimated affinity value for each antagonist (pK b ) was calculated using the Gaddum equation from the shift of the agonist-dose−response curve brought about by the addition of a single concentration of the antagonist.
c Measured in competition binding experiments with fluorescent ligand 98. 
Article respectively. The NMR data was processed using iNMR (version 5.5.7), which referenced the spectra to those of the residual solvents. Chemical shifts (δ) are quoted as values in parts per million, and coupling constants (J) are given in hertz. Multiplicities are described using the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; qi, quintet; sep, septet; m, multiplet; app, apparent; and br, broad. All compounds submitted for biological screening had purities >95%.
General Procedure 1: Substitution of 2-Chlorothiazole to Generate 2-Aminothiazoles. A stirred solution of 43 (0.15− 0.50 mmol) dissolved in anhydrous 1,4-dioxane (0.1 M, 1.5−5.0 mL) was treated with a chosen amine (4 equiv, 0.45−2.00 mmol) and triethyl amine (10 equiv, 1.50−5.00 mmol) under N 2 and either heated to reflux for 36−72 h until completion was observed by TLC or LC-MS or heated in a microwave reactor at 100°C for 4 h. The reaction mixture was concentrated in vacuo directly onto a silica gel and purified by chromatography on a silica gel (2−5% MeOH/DCM with 0.1% 880 NH 3 ) to afford the desired 2-aminothiazoles, 45−56.
General Procedure 2: Thionation of Uracils to 4-Thiouracils Using Lawesson's Reagent. Stirred suspensions or solutions of the uracils (0.05−0.25 mmol) and Lawesson's reagent (2 stoichiometric equiv/1 molar equiv, 0.05−0.25 mmol) in anhydrous 1,4-dioxane (0.05 M, 1−5 mL) were heated to reflux (120°C) under N 2 for 18 h, generating deep-yellow-orange solutions. These were allowed to cool to room temperature, and the crude reaction mixtures were concentrated in vacuo onto silica gels, and unless otherwise stated, the title compounds were purified by chromatography on silica gels and eluted with 0−5% MeOH/DCM to afford the desired 4-thiouracils.
General Procedure 3: Synthesis of BODIPY-Labeled Fluorescent Conjugates. A solution of a Boc-protected amine (2.00 μmol) dissolved in DCM (0.50 mL) was treated with TFA (0.25 mL) and stirred at rt for 30 min. This was then diluted with toluene (10 mL) and concentrated in vacuo to one-fifth the volume; this was repeated three times before the solution was concentrated to dryness, affording the TFA salt of the conjugate. This was dissolved in DMF (500 μL), treated with DIPEA (25 μL) and then with a solution of BODIPYFL-X-NHS (1.00 mg, 2.00 μmol) in DMF (150 μL), BODIPY630/650-X-NHS (1.32 mg, 2.00 μmol) in DMF (150 μL), BODIPYFL-NHS, or BODIPY630/650-NHS; the latter two were generated in situ by mixing BODIPYFL-CO 2 H X (0.78 mg, 2.00 μmol) or BODIPY630/ 650-CO 2 H (0.90 mg, 2.00 μmol) with HATU (0.76 mg, 2.00 μmol), NHS (0.23 mg, 2.00 μmol), and DIPEA (25 μL) in DMF (150 μL) for 30 min before they were added. The solution was then allowed to react at room temperature in the absence of light for 1−4 h until completion was observed by LC-MS. The desired fluorescent conjugate was then purified directly from the reaction mixture by preparative reversephase HPLC and lyophilization.
2 
A stirred solution of 36 (65 mg, 0.120 mmol) in MeOH (10 mL) was treated with 2 M NaOH (0.18 mL, 0.36 mmol) and heated to reflux for 30 min under N 2 . Completion was observed by TLC, and the RM was concentrated to one-third the volume, diluted with ethyl acetate (20 mL), washed with 1 M HCl (10 mL) and brine (10 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford the corresponding acid as an orange solid (60 mg). A stirred solution of the acid (30 mg, 0.058 mmol) in DMF (3 mL) was treated with DIPEA (40 μL) and 5-aminotetrazole monohydrate (12 mg, 0.117 mmol) followed by PyBroP (41 mg, 0.087 mmol) and stirred at rt for 2 h until completion was observed by LC-MS. The RM was quenched with water (ca. two drops), diluted with ethyl acetate (20 mL), and partitioned with 1 M HCl (10 mL); the organics were extracted with ethyl acetate (2 × 10 mL), combined, washed with brine (10 mL), dried over MgSO 4 , filtered, and concentrated in vacuo. The DMF was azeotroped with toluene (3 × 50 mL) to afford an orange oil. This was purified by being washed with 10% MeOH/DCM before the desired compound was eluted with 10% MeOH/DCM and 1% acetic acid to afford the title compound, 5, as an orange solid (10 mg, 0.017 mmol, 30% 5-(7-Chloro-2-methyl-4H-benzo [5, 6] 5-(2-Amino-7-chloro-4H-benzo [5, 6] 
. Following general procedure 2, 45 (45 mg, 0.121 mmol) was converted to the title compound, 7, and isolated at 2% MeOH/DCM as a yellow solid 
Following general procedure 2, 46 (45 mg, 0.100 mmol) was converted to the title compound, 8, which was isolated at 2% MeOH/ DCM as a yellow solid (39 mg, 0.084 mmol, 84% 5-(7-Chloro-2-(piperidin-1-yl)-4H-benzo [5, 6] (13) . Following general procedure 2, 51 (44 mg, 0.100 mmol) was converted to the title compound, 13, which was isolated at 2% MeOH/ DCM as a yellow solid (34 mg, 0.074 mmol, 74% 5- The two enantiomers were isolated by chiral-HPLC: 22 (Rt: 28.32 min, 95% ee) and 23 (Rt: 36.68 min, 96% ee).
5- 5-(7-Chloro-2-phenyl-4H-benzo [5, 6] + . The acid (20 mg, 0.035 mmol) in DMF (1.5 mL) was treated with DIPEA (50 μL) and 5-aminotetrazole monohydrate (22 mg, 0.203 mmol) followed by PyBroP (24 mg, 0.051 mmol) and stirred at rt for 2 h until completion was observed by LC-MS. The RM was quenched with water (ca. two drops), diluted with EA (20 mL), and partitioned with 1 M HCl (10 mL), and the organics were extracted with EA (2 × 10 mL), combined, washed with brine (10 mL), dried over MgSO 4 , filtered, and concentrated in vacuo. The DMF was azeotroped with toluene (3 × 50 mL) to afford an orange oil. This was purified by being washed with 10% MeOH/DCM before the desired compound was eluted with 10% MeOH/DCM with 1% acetic acid to afford the title compound. Further purification was achieved by preparative RP-HPLC (Method 3), isolating the title compound, 24, at a retention time of 7.37 3-(3-Chlorophenyl)propanal (26) . A stirred solution of 3-chloroiodobenzene (50.00 g, 210 mmol), allyl alcohol (21.4 mL, 18.27 g, 314 mmol), tetrabutylammonium chloride (58.26 g, 210 mmol), and NaHCO 3 (17.61 g, 210 mmol) dissolved in anhydrous DMF (150 mL) and cooled in an ice bath under N 2 was treated portionwise with Pd(OAc) 2 (1.40 g, 6.29 mmol) over 30 min. This was then heated to 50°C for 18 h, and the consumption of 3-chloroiodobenzene was observed by TLC (15% ethyl acetate/petroleum ether). The reaction was concentrated in vacuo, and the DMF was azeotroped with toluene (3 × 200 mL). The resulting black gum was dissolved in Et 2 O (300 mL) and water (300 mL) and filtered, and the organics were extracted with Et 2 O (2 × 300 mL), combined, washed with brine (100 mL), dried over MgSO 4 , and concentrated in vacuo to afford a black oil. Further purification was achieved by FC (10−40% Et 2 O/ PE), to afford the title compound, 27 (32. 30 Ethyl 5-(3-Chlorophenethyl)-2-methylthiazole-4-carboxylate (27) . A stirred solution of 26 (24.00 g, 143 mmol) and ethyl dichloroacetate (22.42 g, 143 mmol) dissolved in anhydrous diethyl ether (120 mL) and cooled to below −10°C in an ice−salt bath under N 2 was treated with a freshly prepared solution of sodium ethoxide (2.2 M, 50 mL, 110 mmol) over a 15 min period, and we ensured that the temperature did not rise above 0°C. This generated a pale-orange suspension. This was stirred for 45 min and then warmed to 40°C over 30 min. This was then quenched with water (250 mL), and the organics were extracted with diethyl ether (3 × 150 mL). These were combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford to afford an orange oil. This was dissolved in ethanol (80 mL) and added dropwise to a warm solution of thioacetamide (16.09 g, 214 mmol) in ethanol (80 mL) that had been heated to 65°C over a 10 min period. This was heated to reflux for 3 h, generating a red solution with a white precipitate, which was allowed to cool to rt and concentrated in vacuo. The residue was then diluted with diethyl ether (200 mL) and partitioned with NaHCO 3 (100 mL) and water (100 mL). The organics where extracted with diethyl ether (3 × 200 mL), combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford a brown oil. This was purified by FC (10−30% ethyl acetate/petroleum ether) to afford the title compound, 27, at 15% ethyl acetate/ petroleum ether as a yellow solid (13.21 
5-(3-Chlorophenethyl)-2-methylthiazole-4-carboxylic Acid (28).
A stirred solution of 27 (13.00 g, 42.0 mmol) in THF (60 mL) was treated with a solution of NaOH (2.52g, 63.0 mmol) in water (60 mL). This was stirred for 24 h at rt and treated with 2 M HCl (100 mL), and the organics were extracted with ethyl acetate (3 × 100 mL), combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford the title compound, 28, as a paleyellow solid (11.68 g, 41.4 mmol, 99%). 1 7-Chloro-2-methyl-9,10-dihydro-4H-benzo [5, 6] 
cyclohepta[1,2-d]thiazol-4-one (29).
A stirred solution of 28 (11.27 g, 40 mmol) in DCM (120 mL) under N 2 was treated with oxalyl chloride (6.00 mL, 70 mmol) and catalytic DMF (ca. two drops) and stirred for 3 h at rt. This was then concentrated in vacuo. The residual oxalyl chloride was azeotroped with toluene (3 × 50 mL) to afford an orange solid. This was dissolved in DCM (175 mL), cooled in an ice bath under N 2 , and treated portionwise with aluminum(III)chloride (21.33 g, 160 mmol), generating a black solution. This was allowed to warm to rt and was stirred for 18 h. This was gradually added to a stirred slurry of ice and 2 M HCl (400 mL) and allowed to warm to rt. The organics were extracted with ethyl acetate (3 × 400 mL), combined, washed with brine (300 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford a crude solid. This was purified by FC (20−100% ethyl acetate/petroleum ether) to afford the title compound, 29, at 50% ethyl acetate/petroleum ether as a beige solid (4.16 g, 15.6 
5-Bromo-2,4-di-tert-butoxypyrimidine (31).
To a stirred solution of 5-bromo-2,4-dichloropyrimidine (5.00 g, 22.00 mmol) in anhydrous THF (70 mL) cooled in an ice bath under N 2 , a suspension of sodium tert-butoxide (6.35 g, 66.0 mmol) in anhydrous THF (50 mL) was added dropwise via a dropping funnel over a 30 min period. This was allowed to warm to rt and was stirred for a further 18 h, generating a dark-brown solution. The RM was then quenched with NH 4 Cl(aq) (10 mL) and diluted with water (100 mL), and the organics were extracted with ethyl acetate (3 × 75 mL), combined, washed with brine (50 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford a black oil. Further purification was achieved by FC (2.5% diethyl ether/petroleum ether with 0.1% Et 3 N) to afford the title compound, 31, as a clear oil that crystallized to a white solid on standing (4.08 g, 13.50 7-Chloro-4-(2,4-di-tert-butoxypyrimidin-5-yl)-2-methyl-9,10-dihydro-4H-benzo [5, 6] 10 .00 mmol) that had been dissolved in unstabilized, anhydrous THF (20 mL); stirred at −78°C for 15 min; allowed to warm to rt; and stirred again for 1 h. The RM was then quenched with NH 4 Cl (50 mL) and diluted with water (50 mL), and the organics were extracted with ethyl acetate (3 × 100 mL). These were combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford an orange oil. Further purification was achieved by FC (5−20% ethyl acetate/ petroleum ether) affording the title compound, 32, at 15% ethyl acetate/petroleum ether as a clear oil that foamed and crystallized to a white solid under high vacuum (3.04 g, 6.23 5-(7-Chloro-2-methyl-4H-benzo [5, 6] 29 g, 110 mmol) , dissolved in anhydrous diethyl ether (90 mL) and cooled to below −10°C in an ice−salt bath under N 2 , was treated with a freshly prepared solution of sodium ethoxide (2.2M, 50 mL, 110 mmol) over a 15 min period, and we ensured that the temperature did not rise above 0°C. This generated a pale-orange suspension, which was stirred for 45 min and warmed to 40°C over 30 min. This was then quenched with water (250 mL), and the organics were extracted with diethyl ether (3 × 150 mL). These were combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford to afford an orange oil. This was dissolved in ethanol (60 mL) and added dropwise to a warm solution of thiourea (12.56 g, 165 mmol) in ethanol (60 mL) that had been heated to 65°C over a 10 min period. This was heated to reflux for 2.5 h, generating a purplered solution and a white precipitate, which was then allowed to cool to rt and concentrated in vacuo. The residue was then diluted with diethyl ether (200 mL) and partitioned with NaHCO 3 (100 mL) and water (100 mL). The organics were extracted with diethyl ether (3 × 200 mL), combined, washed with brine (100 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford a brown oil. This was taken up in a diethyl ether (100 mL), filtered through a plug of silica, and washed with diethyl ether (3 × 200 mL). The filtrate was concentrated to afford an orange solid, which was triturated with diethyl ether/hexane to give the title compound, 37, as a yellow solid (15.70 2-Chloro-5-(3-chlorophenethyl)thiazole-4-carboxylic Acid (39). A stirred solution of 38 (10.00 g, 30. 3 mmol) in THF (40 mL) was treated with a solution of NaOH (1.817 g, 45.4 mmol) in water (40 mL). This was stirred for 24 h at rt and treated with 2 M HCl (100 mL). The organics were extracted with ethyl acetate (3 × 100 mL), combined, washed with brine (50 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford the title compound, 39, as a paleyellow solid (9.15 g, 30.3 2,7-Dichloro-4-(2,4-di-tert-butoxypyrimidin-5-yl)-9,10-dihydro-4H-benzo [5, 6] 5 .00 mmol) that had been dissolved in unstabilized, anhydrous THF (10 mL); stirred at −78°C for 15 min; allowed to warm to rt; and stirred for 1 h. The RM was then quenched with NH 4 Cl(aq) (20 mL) and diluted with water (20 mL), and the organics were extracted with ethyl acetate (3 × 50 mL). These were combined, washed with brine (20 mL), dried over MgSO 4 , filtered, and concentrated in vacuo to afford an orange oil. and heated to 50°C for 6 h until completion was observed by LC-MS. This was concentrated in vacuo to afford an orange oil, which was dissolved in MeOH and reconcentrated in vacuo to afford a yellow solid. This was triturated with diethyl ether (3 × 30 mL) to afford the title compound, 43 an orange solid (1.466 g, 3.73 6 .87 (d, J = 0.9 Hz, 1H), 5.50 (s, 1H), 3.14 (s, 3H) . 13 C NMR (101 MHz, DMSO-d 6 ) δ: 163.1, 151.1, 150.6, 148.8, 143.2, 136.2, 134.8, 133.2,  132.1, 131.8, 131.5, 130.2, 129.7, 120.6, 108.4, 43.9, 36 .0.
5-(7-Chloro-2-phenyl-4H-benzo [5, 6] 5-(7-Chloro-2-(phenethylamino)-4H-benzo [5, 6] 163.3, 151.1, 148.0, 143.0, 139.7, 137.1, 134.1,  133.1, 131.0, 129.32, 129.16, 128.8, 128.2, 126.6, 126.1, 122.2, 116.8,  108.9, 46.2, 43.9, 36.2, 35.1 . 5-(7-Chloro-2-morpholino-4H-benzo [5, 6] 
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Article that had been dissolved in 1,2-dichloroethane (3 mL) and refluxed for 72 h. This was concentrated in vacuo to a gum, treated with MeOH (20 mL), and then reconcentrated in vacuo to a brown solid. This was triturated with diethyl ether (3 × 50 mL) to give the title compound, 57, as a brown solid (1.125 3.23 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H). 13 C NMR (126 MHz, DMSO-d 6 ) δ: 189. 8, 169.3, 165.5, 161.0, 147.9, 146.4, 141.9, 137.5, 133.7, 132.1, 130.93, 130.81, 128.9, 127.8, 126.7, 122.7, 117.6, 116.7, 70.6, 61.4, 58.4 Step C: A sodium hydroxide solution (0.4 mmol, 0.4 mL of a 1 M solution in water) was added to a mixture of the product from step B (0.11 g, 0.2 mmol) in methanol (1 mL), toluene (0.5 mL), and water (0.5 mL). After 4 h, the reaction mixture was partitioned between 2 M hydrochloric acid and ethyl acetate. The ethyl acetate layer was washed with brine, dried (magnesium sulfate), filtered, and evaporated in vacuo. Purification was by silica-gel chromatography, and the eluents were 2% acetic acid in ethyl acetate/toluene (25: in DMF (2 mL). After 0.5 h, the solution was diluted with ethyl acetate (15 mL) and washed with water (2 × 4 mL) and brine (1 × 4 mL). The solution was evaporate to dryness under reduced pressure. Purification was by silica-gel chromatography, and the eluent was ethyl acetate. Yield: 0.09 g, 0.12 mmol, 63% (yellow solid). 1 H NMR (400 MHz, DMSO) δ: 12.61 (s, 1H), 8.89 (t, J = 5.5 Hz, 1H), 8.48 (t, J = 1.6 Hz, 1H), 8.05 (t, J = 1.7 Hz, 1H), 8 .00 (t, J = 1.6 Hz, 1H), 7 .44 (d, J = 7.9 Hz, 2H), 7.14 (ddd, J = 7.8, 1.9, 0.8 Hz, 2H), 7.05 (dd, J = 1.9, 0.8 Hz, 2H), 6 .94 (s, 1H), 6 .76 (t, J = 5.6 Hz, 1H), 6.62 tert tert-Butyl 6-((7-Chloro-4-(1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-benzo [5, 6] (E)-N-(2-(3-((7-Chloro-4-(1-methyl-2-oxo-4-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-4H-benzo [5, 6] 
Article using a 40× c-Apochromat 1.2NA water-immersion objective. For 97, the images were collected using a 633 nm excitation wavelength and a 488/561/633 dichroic, and the emissions were collected through a 650LP filter. For 98, a 488 nm excitation wavelength was used with the same dichroic, and the emissions were collected using an LP575 filter. In each case, a pinhole diameter of 1 airy unit was used, and the laser power, gain, and offset were kept the same for all of the samples within each experiment. For both 97 and 98, the images presented are as representative of an individual experiment with matched conditions. Linear adjustments to the image brightness and contrast have been applied equally across all of the comparative images using Zen software in order to prepare the images for presentation.
Data Analysis. All of the data were analyzed using GraphPad Prism 6.
For the calcium-mobilization experiments, as none of the compounds synthesized as part of this study showed any partialagonist actions, the estimated affinity values (pK b ) were calculated from the shifts of the agonist-concentration−response curves in the presence of the fluorescent antagonists using eq 1:
where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of the antagonist, b. The pK b is −log K b .
The total and nonspecific saturation binding curves were fitted simultaneously using eq 2:
where B max is the maximum specific BRET signal, [b] is the nanomolar concentration of the fluorescent ligand, K d is the equilibrium dissociation constant in nanomolar, M is the slope of the nonspecificbinding component, and C is the intercept with the Y-axis. The pK d is −logK d . The competition binding curves were fitted using eq 3: 
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